Genflow Biosciences PLC Announces Temporary Suspension
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET...
Clinical Trial
Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA
Significant POLB 001 Patent Granted in United StatesImmunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering LONDON,...
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
$25 million funded at close; up to $25 million of additional capital available at the Company’s option, based on the...
Reimagine Care Unveils Expansion of Distinguished Clinical Advisory Board to Advance Virtual-first Cancer Care Innovation
NASHVILLE, Tenn.--(BUSINESS WIRE)--Reimagine Care, the nation’s leading provider of virtual-first cancer care, proudly announces the expansion of its esteemed Clinical...
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 30, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release...
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
TORONTO, ON / ACCESSWIRE / April 30, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" of the "Company"), a biopharmaceutical...
Halberd’s Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans
LDN+ Drug Designed to Combat PTSD and Suicidal IdeationJACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation...
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum...
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
ASSESSING THE EFECTS OF MICRODOSING MB22001 IN MENSTRUATING PERSONS WITH AND WITHOUT PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER Multiple clinical trials...
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia
Cannabix is developing alcohol and marijuana breathalyzer devices to give law enforcement and employers a tool to enhance public safetyVANCOUVER,...
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita® in patients with...
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024CAMBRIDGE, Mass., April 30, 2024 (GLOBE NEWSWIRE) --...
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline...
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure
DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions...
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts
POMPANO BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused...
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
– Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML – – Data...
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
– A-005 is a potential first-in-class, CNS penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – –...
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through...
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
Independent Safety Committee approves increase of RECCE® 327 (R327) dose to 4,000mg intravenously (IV) over 30 minutes for six subjects,...
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals,...